Terms: = Breast cancer AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546 AND Treatment
73 results:
1. Changes in lymph node surgery in breast cancer and preoperative drug prescription analysis for postoperative pain management: A retrospective, cross-sectional study.
Kang ES; Lim YC; Jang BH; Lee YJ; Ha IH; Lee YS
PLoS One; 2024; 19(4):e0298270. PubMed ID: 38574043
[TBL] [Abstract] [Full Text] [Related]
2. Diagnostic value of applying preoperative breast ultrasound and clinicopathologic features to predict axillary lymph node burden in early invasive breast cancer: a study of 1247 patients.
Shao H; Sun Y; Na Z; Jing H; Li B; Wang Q; Zhang C; Cheng W
BMC Cancer; 2024 Jan; 24(1):112. PubMed ID: 38254060
[TBL] [Abstract] [Full Text] [Related]
3. Expression of neuroendocrine markers predicts increased survival in triple-negative breast cancer patients.
Xia C; Shen S; Pang J; Chen L; Yan J; Liang Z; Ren X
Front Endocrinol (Lausanne); 2023; 14():1205631. PubMed ID: 38125789
[TBL] [Abstract] [Full Text] [Related]
4. Effects of occupational therapy on quality of life in breast cancer patients: A systematic review and meta-analysis.
He K; Jiang J; Chen M; Wang T; Huang X; Zhu R; Zhang Z; Chen J; Zhao L
Medicine (Baltimore); 2023 Aug; 102(31):e34484. PubMed ID: 37543817
[TBL] [Abstract] [Full Text] [Related]
5. Seroma After breast Reconstruction With Tissue Expanders: Outcomes and Management.
Ozturk CN; Ozturk C; Magner WJ; Ali A; Diehl J; Sigurdson SL
Ann Plast Surg; 2023 Sep; 91(3):331-336. PubMed ID: 37347178
[TBL] [Abstract] [Full Text] [Related]
6. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.
Villacampa G; Tung NM; Pernas S; Paré L; Bueno-Muiño C; Echavarría I; López-Tarruella S; Roche-Molina M; Del Monte-Millán M; Marín-Aguilera M; Brasó-Maristany F; Waks AG; Pascual T; Martínez-Sáez O; Vivancos A; Conte PF; Guarneri V; Vittoria Dieci M; Griguolo G; Cortés J; Llombart-Cussac A; Muñoz M; Vidal M; Adamo B; Wolff AC; DeMichele A; Villagrasa P; Parker JS; Perou CM; Fernandez-Martinez A; Carey LA; Mittendorf EA; Martín M; Prat A; Tolaney SM
Ann Oncol; 2023 Sep; 34(9):783-795. PubMed ID: 37302750
[TBL] [Abstract] [Full Text] [Related]
7. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.
Miyashita M; Bell JSK; Wenric S; Karaesmen E; Rhead B; Kase M; Kaneva K; De La Vega FM; Zheng Y; Yoshimatsu TF; Khramtsova G; Liu F; Zhao F; Howard FM; Nanda R; Beaubier N; White KP; Huo D; Olopade OI
Breast Cancer Res; 2023 May; 25(1):58. PubMed ID: 37231433
[TBL] [Abstract] [Full Text] [Related]
8. Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226).
Bergqvist M; Nordmark A; Williams A; Paoletti C; Barlow W; Cobain EF; Mehta RS; Gralow JR; Hortobagyi GN; Albain KS; Pusztai L; Sharma P; Godwin AK; Thompson AM; Hayes DF; Rae JM
Biomarkers; 2023 May; 28(3):313-322. PubMed ID: 36647745
[TBL] [Abstract] [Full Text] [Related]
9. Underreporting and Underrepresentation of Racial and Ethnic Minority Patients in Lymphedema Clinical Trials: A Systematic Review.
Escobar-Domingo MJ; Bustos VP; Fanning JE; Foppiani J; Kim E; Hernandez-Alvarez A; Lin SJ; Singhal D; Lee BT
Lymphology; 2023; 56(2):41-60. PubMed ID: 38621383
[TBL] [Abstract] [Full Text] [Related]
10. breast-Specific Sensuality in breast cancer Survivors: Sexually Active or Not.
Peifer HG; Raker C; Pesek S; Edmonson D; Stuckey A; Gass JS
Ann Surg Oncol; 2022 Oct; 29(10):6225-6233. PubMed ID: 35951135
[TBL] [Abstract] [Full Text] [Related]
11. AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.
Bardia A; Chandarlapaty S; Linden HM; Ulaner GA; Gosselin A; Cartot-Cotton S; Cohen P; Doroumian S; Paux G; Celanovic M; Pelekanou V; Ming JE; Ternès N; Bouaboula M; Lee JS; Bauchet AL; Campone M
Nat Commun; 2022 Jul; 13(1):4116. PubMed ID: 35840573
[TBL] [Abstract] [Full Text] [Related]
12. Long-Term Complications and Patient-Reported Outcomes After Alloplastic breast Reconstruction.
Lee CC; Perng CK; Ma H; Wu SH; Hsiao FY; Tseng LM; Tsai YF; Lin YS; Lien PJ; Feng CJ
Ann Plast Surg; 2022 Mar; 88(1s Suppl 1):S78-S84. PubMed ID: 35225852
[TBL] [Abstract] [Full Text] [Related]
13. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Aghajanian C; Swisher EM; Okamoto A; Steffensen KD; Bookman MA; Fleming GF; Friedlander M; Moore KN; Tewari KS; O'Malley DM; Chan JK; Ratajczak C; Hashiba H; Wu M; Dinh MH; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):278-287. PubMed ID: 34930617
[TBL] [Abstract] [Full Text] [Related]
14. Toxicity and Cosmetic Outcome of breast Irradiation in Women with breast cancer and Autoimmune Connective Tissue Disease: The Role of Fraction and Field Size.
Purswani JM; Jaros B; Oh C; Sandigursky S; Xiao J; Gerber NK
Pract Radiat Oncol; 2022; 12(2):e90-e100. PubMed ID: 34774868
[TBL] [Abstract] [Full Text] [Related]
15. Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients.
Corné J; Le Du F; Quillien V; Godey F; Robert L; Bourien H; Brunot A; Crouzet L; Perrin C; Lefeuvre-Plesse C; Diéras V; De la Motte Rouge T
Sci Rep; 2021 Aug; 11(1):17316. PubMed ID: 34453076
[TBL] [Abstract] [Full Text] [Related]
16. A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive breast cancer.
Jhaveri K; Juric D; Yap YS; Cresta S; Layman RM; Duhoux FP; Terret C; Takahashi S; Huober J; Kundamal N; Sheng Q; Balbin A; Ji Y; He W; Crystal A; De Vita S; Curigliano G
Clin Cancer Res; 2021 Nov; 27(21):5760-5770. PubMed ID: 34433648
[TBL] [Abstract] [Full Text] [Related]
17. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract] [Full Text] [Related]
18. Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive breast cancer Survivors.
He X; Ji J; Dai X; Qdaisat AZ; Esteva FJ; Hortobagyi GN; Yeung SJ
Clin Cancer Res; 2021 Oct; 27(19):5343-5352. PubMed ID: 34117035
[TBL] [Abstract] [Full Text] [Related]
19. Nomogram for predicting preoperative regional lymph nodes metastasis in patients with metaplastic breast cancer: a SEER population-based study.
Zhang M; Wang B; Liu N; Wang H; Zhang J; Wu L; Zhao A; Wang L; Zhao X; Yang J
BMC Cancer; 2021 May; 21(1):565. PubMed ID: 34001061
[TBL] [Abstract] [Full Text] [Related]
20. First-line Gemcitabine
Yamamoto S; Narui K; Ishikawa T; Adachi S; Shimada K; Shimizu D; Yamada A; Sugae S; Tanabe M; Oba M; Morita S; Doi T; Hasegawa S; Morita T; Kito A; Chishima T; Ichikawa Y; Endo I;
Anticancer Res; 2021 Mar; 41(3):1671-1676. PubMed ID: 33788764
[TBL] [Abstract] [Full Text] [Related]
[Next]
